Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter open-label phase Ib/II study of JS001 in advanced gastric adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, and head and neck squamous cell carcinoma
CTR20160740Phase 2Completed
- Sponsor
- Junshi Biosciences
- Start
- Dec 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in gastric adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC), nasopharyngeal carcinoma (NPC), head and neck squamous cell carcinoma (HNSCC), sponsored by Junshi Biosciences. Started Dec 2016; status: completed.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)nasopharyngeal carcinoma (NPC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20160740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160740.